Impact of 2023 Updated IDSA Guidelines on Antimicrobial Resistant Gram-Negative Infection Treatment

Opinion
Video

Dr Christian Sandrock evaluates the impact of 2023 updated IDSA guidelines on treatment decisions for patients with antimicrobial resistant gram-negative infections and for patients with multidrug-resistant pathogens.

Related Videos
Related Content
FDA Approves Antibiotic for Uncomplicated UTIs

FDA Approves Antibiotic for Uncomplicated UTIs

April 24th 2024
Article
The Latest Updates on Managing Your Patients With Antimicrobial Resistant Gram-Negative Infections

The Latest Updates on Managing Your Patients With Antimicrobial Resistant Gram-Negative Infections

November 8th 2023
Podcast
Antibiotics for Most Lower Tract Respiratory Infections Are Not Efficacious

Antibiotics for Most Lower Tract Respiratory Infections Are Not Efficacious

April 17th 2024
Article
Expert Guidance on Managing Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in an Outpatient Setting

Expert Guidance on Managing Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in an Outpatient Setting

November 7th 2023
Podcast
Oral UTI Vaccine Demonstrates Long-Term Efficacy in Over Half of Recipients

Oral UTI Vaccine Demonstrates Long-Term Efficacy in Over Half of Recipients

April 7th 2024
Article
Considerations for Antimicrobial Stewardship While Optimizing Therapy for a Patient With HIV

Considerations for Antimicrobial Stewardship While Optimizing Therapy for a Patient With HIV

April 3rd 2024
Article
© 2024 MJH Life Sciences

All rights reserved.